Multitarget Stool DNA for Average Risk Colorectal Cancer Screening: Major Achievements and Future Directions

John B. Kisiel, Jason D. Eckmann, Paul J. Limburg

Research output: Contribution to journalReview article

Abstract

After 2 screen-setting studies showing high sensitivity for colorectal cancer and advanced precancerous lesions, multitarget stool DNA testing was endorsed by the US Preventative Services Task Force as a first-line colorectal cancer screening test. Uptake has increased exponentially since approval by the US Food and Drug Administration and Centers for Medicare and Medicaid Services. Adherence to testing is approximately 70%. Patients with positive results have high diagnostic colonoscopy completion rates in single-center studies. The positive predictive value for colorectal neoplasia in postapproval studies is high. Next-generation test prototypes show promise to extend specificity gains while maintaining high sensitivity.

Original languageEnglish (US)
Pages (from-to)553-568
Number of pages16
JournalGastrointestinal Endoscopy Clinics of North America
Volume30
Issue number3
DOIs
StatePublished - Jul 2020

Keywords

  • Colonoscopy/trends
  • Colorectal neoplasms/diagnosis
  • Colorectal neoplasms/prevention and control
  • DNA
  • Early detection of cancer/methods
  • Neoplasm/analysis
  • Precancerous conditions/diagnosis
  • Proximal colorectal neoplasia

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Multitarget Stool DNA for Average Risk Colorectal Cancer Screening: Major Achievements and Future Directions'. Together they form a unique fingerprint.

  • Cite this